

Co., Ltd. of Shanghai, China (“Shanghai Chemtron”). See *id.* The complaint and notice of investigation were later amended to add two respondents, 12Panel Now, Inc. and Hospital Connect, Inc., both of Boynton Beach, Florida. Order No. 8 (March 9, 2021), *unreviewed by* 86 FR 16640–41 (March 30, 2021).

The Commission previously terminated six respondents based on consent orders. Order Nos. 11 and 12 (Mar. 31, 2021), *unreviewed by* Comm’n Notice (Apr. 15, 2021) (TransMed Co., LLC, 12PanelMedical, Inc., 12Panel Now, Inc., and Hospital Connect, Inc.); Order No. 14 (April 9, 2021), *unreviewed by* Comm’n Notice (Apr. 22, 2021) (Mercedes Medical, LLC); Order No. 15 (April 12, 2021), *unreviewed by* Comm’n Notice (May 12, 2021) (Transmetron Inc.). The Commission also previously terminated four respondents based on settlement agreements. Order No. 13 (Apr. 5, 2021), *unreviewed by* Comm’n Notice (Apr. 19, 2021) (Confirm Biosciences, Inc.); Order No. 17 (May 5, 2021), *unreviewed by* Comm’n Notice (May 18, 2021) (AlcoPro, Inc.); Order No. 18 (May 20, 2021), *unreviewed by* Comm’n Notice (June 21, 2021) (American Screening, LLC); Order No. 29 (Jan. 31, 2022), *unreviewed by* 87 FR 11096–98 (Feb. 28, 2022) (Shanghai Chemtron). The Commission also terminated five respondents based on partial withdrawal of the complaint. Order No. 20 (June 4, 2021), *unreviewed by* Comm’n Notice (June 28, 2021) (Chemtron Biotech, Inc.); Order No. 21 (June 14, 2021), *unreviewed by* Comm’n Notice (July 1, 2021) (Hangzhou AllTest Biotech Co., Ltd.; Acro Biotech, Inc.; Zhejiang Orient Gene Biotech Co, Ltd.; Healgen Scientific, LLC).

On May 18, 2021, the Commission determined not to review an initial determination (Order No. 16) finding Kappa City in default. Order No. 16 (Apr. 30, 2021), *unreviewed by* Comm’n Notice (May 18, 2021).

On December 7, 2021, ARK filed a declaration seeking immediate entry of a limited exclusion order and cease and desist order against Kappa City.

On February 22, 2022, the Commission determined not to review an initial determination granting a motion to terminate Shanghai Chemtron based on settlement. See Order No. 29 (Jan. 31, 2022), *unreviewed by* 87 FR 11096–98 (Feb. 28, 2022). The Commission concurrently determined that ARK’s declaration was moot given the termination of the final remaining non-defaulting respondent in this investigation. 87 FR at 11097. The Commission also requested briefing on

the issues of remedy, bonding, and the public interest. *Id.*

On March 8, 2022, ARK filed the sole response to the Commission’s request for briefing. No replies or other submissions were received.

Upon review of the record, including ARK’s submission, and in the absence of any response from Kappa City or from other interested persons or government agencies, the Commission has determined to issue a limited exclusion order against Kappa City pursuant to section 337(g)(1). The Commission has determined not to issue a cease and desist order against Kappa City, which is a foreign respondent. See, e.g., *In the Matter of Certain Powered Cover Plates*, Inv. No. 337–TA–1124, Comm’n Op. at 24–28 (July 10, 2020); *Certain Earpiece Devices and Components Thereof*, Inv. No. 337–TA–1121, Comm’n Op. at 42–44 (Nov. 9, 2019); *Certain Electric Skin Care Devices, Brushes and Chargers Therefore, and Kits Containing the Same*, Inv. No. 337–TA–959, Comm’n Op. at 28–33 (Feb. 13, 2017). The Commission has determined that the public interest factors do not preclude issuance of the remedial order. The Commission has further determined to set a bond in the amount of one hundred (100) percent of the entered value of the covered products imported during the period of Presidential review (19 U.S.C. 1337(j)). The Commission’s order was delivered to the President and the United States Trade Representative on the day of its issuance. The investigation is hereby terminated.

Commissioners Schmidlein and Karpel would issue both a limited exclusion order and a cease and desist order against Kappa City pursuant to section 337(g)(1) because all requirements of this provision are met. 19 U.S.C. 1337(g)(1)(A)–(E). Specifically, Kappa City was named in the complaint and was served the complaint and notice of investigation. See Order No. 16 (Apr. 30, 2021), *unreviewed by* Comm’n Notice (May 18, 2021). Kappa City failed to show good cause why it should not be held in default for failing to respond to the complaint and notice of investigation. See *id.* These findings satisfy subsections 337(g)(1)(A)–(D). ARK requested a limited exclusion order and a cease and desist order against Kappa City satisfying subsection 337(g)(1)(E). Given that subsections 337(g)(1)(A)–(E) are satisfied, the statute directs the Commission to issue the requested limited exclusion order and cease and desist order, subject to consideration of the public interest. Commissioners Schmidlein and Karpel find that issuance of the requested relief would

not adversely impact the public interest factors.

While temporary remote operating procedures are in place in response to COVID–19, the Office of the Secretary is not able to serve parties that have not retained counsel or otherwise provided a point of contact for electronic service. Accordingly, pursuant to Commission Rules 201.16(a) and 210.7(a)(1) (19 CFR 201.16(a), 210.7(a)(1)), the Commission orders that the complainant complete service for any party/parties without a method of electronic service noted on the attached Certificate of Service and shall file proof of service on the Electronic Document Information System (EDIS).

The Commission vote for this determination took place on July 25, 2022.

The authority for the Commission’s determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in part 210 of the Commission’s Rules of Practice and Procedure (19 CFR part 210).

By order of the Commission.

Issued: July 25, 2022.

**Katherine Hiner,**

*Acting Secretary to the Commission.*

[FR Doc. 2022–16261 Filed 7–28–22; 8:45 am]

**BILLING CODE 7020–02–P**

---

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

[Docket No. DEA–1020]

#### Importer of Controlled Substances Application: Usona Institute

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Usona Institute has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTARY INFORMATION** listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before August 29, 2022. Such persons may also file a written request for a hearing on the application on or before August 29, 2022.

**ADDRESSES:** The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal,

which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to <https://www.regulations.gov> and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on <https://www.regulations.gov>. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.34(a), this is notice that on April 27, 2022, Usona Institute, 2780 Woods Hollow Road, Room 2412, Fitchburg, Wisconsin 53711–5370, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
5-Methoxy-N-N-dimethyltryptamine.	7431	I
Dimethyltryptamine ...	7435	I
Psilocybin .....	7437	I
Psilocyn .....	7438	I

The institute plans to import the listed controlled substances to be used for research and analytical purposes. The materials will not be used for clinical trials or bulk manufacture. No other activity for these drug codes is authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

**Kristi O'Malley,**  
Assistant Administrator.

[FR Doc. 2022–16338 Filed 7–28–22; 8:45 am]

**BILLING CODE P**

**DEPARTMENT OF JUSTICE**

**Federal Bureau of Investigation**

[OMB Number 1110–NEW]

**Agency Information Collection Activities; Proposed eCollection eComments Requested; New Collection**

**AGENCY:** Laboratory Division-RSU, Federal Bureau of Investigation, Department of Justice.

**ACTION:** 60-Day notice.

**SUMMARY:** The Laboratory Division-RSU, Federal Bureau of Investigation, Department of Justice, is submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.

**DATES:** The Department of Justice encourages public comment and will accept input until September 27, 2022.

**FOR FURTHER INFORMATION CONTACT:** If you have additional comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact Libby Stern, Research Chemist, Federal Bureau of Investigation Laboratory Division, Research and Support Unit, 2501 Investigation Ave, Quantico, VA 22135, [geophysics@fbi.gov](mailto:geophysics@fbi.gov), 703–632–7825.

**SUPPLEMENTARY INFORMATION:** Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:

- > Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the Federal Bureau of Investigation, Laboratory Division-RSU, including whether the information will have practical utility;
- > Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;
- > Evaluate whether and if so how the quality, utility, and clarity of the information to be collected can be enhanced; and
- > Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other

technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses.

**Overview of This Information Collection**

1. *Type of Information Collection:* New collection.
2. *The Title of the Form/Collection:* Metal Detector Use in Crime Scene Investigations
3. *The agency form number, if any, and the applicable component of the Department sponsoring the collection:* FBI IRB number 644–22. The applicable component within the Department of Justice is the Federal Bureau of Investigation, Laboratory Division-RSU.
4. *Affected public who will be asked or required to respond, as well as a brief abstract:* Federal Government, State, Local or Tribal Government. Those completing the questionnaires are either active or retired law enforcement personnel. This research study consists of a questionnaire to gather information on the applications metal detectors for law enforcement at crime scene investigations. Participants will be asked what were the composition of law enforcement targets and the environment which they are searching for said targets. An objective of the questionnaire is to learn if advance methods of detection were used to identify suspected targets such as a ground penetrating radar or magnetometer. The results may be published and used to understand applications of metal detectors by law enforcement at crime scenes.
5. *An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond:* We expect no more than 100 individuals completing the questionnaire. On average, we expect an average of 10–15 minutes to complete the questionnaire.
6. *An estimate of the total public burden (in hours) associated with the collection:* 25 hours.

If additional information is required contact: Robert Houser, Assistant Director, Policy and Planning Staff, Justice Management Division, United States Department of Justice, Two Constitution Square, 145 N Street NE, 3E.405A, Washington, DC 20530.

Dated: July 26, 2022.

**Robert Houser,**  
Assistant Director, Policy and Planning Staff,  
Office of the Chief Information Officer, U.S. Department of Justice.

[FR Doc. 2022–16330 Filed 7–28–22; 8:45 am]

**BILLING CODE 4410–02–P**